Keyphrases
Breast Cancer Survivors
40%
Triple-negative Breast Cancer
28%
Chemotherapy
21%
Breast Cancer
21%
Breast Cancer Patients
20%
Metastatic Breast Cancer
19%
Neoadjuvant Chemotherapy
19%
Overall Survival
18%
Advanced Breast Cancer
17%
Single Institution
15%
Phase I Study
14%
Inflammation
14%
Expansion Cohort
11%
Dose Expansion
11%
Dose Escalation
11%
Fractional CO2 Laser
11%
Genitourinary Syndrome of Menopause
11%
Metastatic Triple-negative Breast Cancer
11%
Sacituzumab Govitecan
11%
CDK7 Inhibitor
11%
Female Patients
11%
Pathological Complete Response
10%
Postmenopausal Women
10%
Typhoid Vaccine
9%
Human Epidermal Growth Factor Receptor 2 (HER2)
9%
Empirical Dietary Inflammatory Pattern
8%
Patients with Breast Cancer
8%
Cognitive Decline
8%
Randomized Crossover Trial
8%
Complete Response Rate
8%
Paclitaxel
7%
Proton Pump Inhibitors
7%
Hormone Receptor-positive
7%
Inflammatory Dietary Pattern
7%
Genomic Testing
7%
Patient Perception
7%
Alpelisib
7%
Adjuvant Trastuzumab
7%
HER2+ Breast Cancer
7%
Confidence Interval
7%
Female Sexual Function Index
7%
Progression-free Survival
6%
Disease-free Survival
6%
Tumor
6%
Physical Activity
6%
Interleukin-6
6%
Placebo
6%
Cyclin-dependent Kinase 4 (CDK4)
6%
Self-rated Health
5%
Ovarian Suppression
5%
Medicine and Dentistry
Breast Cancer
100%
Triple Negative Breast Cancer
25%
Metastatic Breast Cancer
22%
Neoplasm
17%
Malignant Neoplasm
16%
Hormone Receptor
16%
Overall Survival
16%
Chemotherapy
15%
Dietary Pattern
14%
Immunity
12%
Neoadjuvant Chemotherapy
11%
Low Level Laser Therapy
11%
Sacituzumab Govitecan
11%
Carbon Dioxide
11%
Body Mass Index
10%
Arm
9%
Adverse Event
9%
Trastuzumab
8%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
8%
Disease Free Survival
8%
Typhoid Vaccine
8%
Progression Free Survival
7%
Alpelisib
7%
Biological Marker
7%
Proton-Pump Inhibitor
7%
Interleukin 6
7%
Cancer
5%
Postmenopause
5%
Nurse
5%
Estrogen Receptor
5%
Capecitabine
5%
Retrospective Study
5%